Information Provided By: 
Fly News Breaks for January 4, 2018
DVA
Jan 4, 2018 | 06:48 EDT
BofA/Merrill analyst Kevin Fischbeck upgraded DaVita to Buy from Neutral, named its a Top Pick, and raised its price target to $85 from $75. Fischbeck thinks DaVita's commercial mix and pricing are stabilizing, which could prove to be a tailwind given conservative initial guidance, and the sale of DaVita Medical Group proceeds can be used for share repurchases, investments, and debt repayment. Further, the analyst sees upside from the shift to MA, tax reform, and EPO savings.
News For DVA From the Last 2 Days
There are no results for your query DVA
